Individual Dosing of ASA Prophylaxis by Controlling Platelet Aggregation
Acetylsalicylic acid is widely used in the primary and secondary prevention of cardiovascular diseases. In the current study, we used platelet aggregation ex vivo in platelet-rich plasma induced with arachidonic acid as a routine method for the determination of the individual dose of acetylsalicylic...
Gespeichert in:
| Veröffentlicht in: | Clinical and applied thrombosis/hemostasis 2001-07, Vol.7 (3), p.209-213 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 213 |
|---|---|
| container_issue | 3 |
| container_start_page | 209 |
| container_title | Clinical and applied thrombosis/hemostasis |
| container_volume | 7 |
| creator | Syrbe, Günter Redlich, Helge Weidlich, Bärbel Ludwig, Jochen Kopitzsch, Sibylle Göckeritz, Anke Herzog, Karin |
| description | Acetylsalicylic acid is widely used in the primary and secondary prevention of cardiovascular diseases. In the current study, we used platelet aggregation ex vivo in platelet-rich plasma induced with arachidonic acid as a routine method for the determination of the individual dose of acetylsalicylic acid necessary to inhibit platelet aggregation in 108 patients with cardiovascular diseases. In 40% of all patients studied, a dose of 30 mg/day was sufficient. to block the arachidonic acid-induced platelet aggregation nearly completely. In 50% of all patients, a dose of 100 mg/day was necessary. In 10% of all patients, the dose had to be further increased to 300 mg/day or even to 500 mg/day to inhibit platelet aggregation nearly completely. These results demonstrate that platelet aggregation can be used as a simple routine laboratory method to control acetylsalicylic acid treatment in patients with cardiovascular diseases and to determine individual doses of acetylsalicylic acid for a nearly complete inhibition of platelet aggregation. With a standard dose of 100 mg/day, 10% of the patients were nonresponders. |
| doi_str_mv | 10.1177/107602960100700305 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_70978234</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_107602960100700305</sage_id><sourcerecordid>2344204721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-5448b084d5f7722b749f72f87429366d43a591038b420be9de09ad8400eae2f83</originalsourceid><addsrcrecordid>eNp90F1LwzAUBuAgipvTP-CFFATv6k4-2iSXZX5sMHCgXpd0TWtH1sykFffvzdhgoOBVAnnOm8OL0DWGe4w5H2PgKRCZAgbgABSSEzTEkoqYcEJPwz2AeCcG6ML7FQCWqUzP0QBjxrAUeIims7ZsvpqyVyZ6sL5p68hWUfaaRQtnNx9bo74bHxXbaGLbzlljdmJhVKeN7qKsrp2uVdfY9hKdVcp4fXU4R-j96fFtMo3nL8-zSTaPlwzjLk4YEwUIViYV54QUnMmKk0pwRiRN05JRlUgMVBSMQKFlqUGqUjAArXRwdITu9rkbZz977bt83filNka12vY-5yC5IJQFePsLrmzv2rBbHp5DOuMEB0X2aums905X-cY1a-W2OYZ813L-t-UwdHOI7ou1Lo8jh1oDGO-BV7U-_vtP5A_IvYIR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2344204721</pqid></control><display><type>article</type><title>Individual Dosing of ASA Prophylaxis by Controlling Platelet Aggregation</title><source>Sage Journals GOLD Open Access 2024</source><creator>Syrbe, Günter ; Redlich, Helge ; Weidlich, Bärbel ; Ludwig, Jochen ; Kopitzsch, Sibylle ; Göckeritz, Anke ; Herzog, Karin</creator><creatorcontrib>Syrbe, Günter ; Redlich, Helge ; Weidlich, Bärbel ; Ludwig, Jochen ; Kopitzsch, Sibylle ; Göckeritz, Anke ; Herzog, Karin</creatorcontrib><description>Acetylsalicylic acid is widely used in the primary and secondary prevention of cardiovascular diseases. In the current study, we used platelet aggregation ex vivo in platelet-rich plasma induced with arachidonic acid as a routine method for the determination of the individual dose of acetylsalicylic acid necessary to inhibit platelet aggregation in 108 patients with cardiovascular diseases. In 40% of all patients studied, a dose of 30 mg/day was sufficient. to block the arachidonic acid-induced platelet aggregation nearly completely. In 50% of all patients, a dose of 100 mg/day was necessary. In 10% of all patients, the dose had to be further increased to 300 mg/day or even to 500 mg/day to inhibit platelet aggregation nearly completely. These results demonstrate that platelet aggregation can be used as a simple routine laboratory method to control acetylsalicylic acid treatment in patients with cardiovascular diseases and to determine individual doses of acetylsalicylic acid for a nearly complete inhibition of platelet aggregation. With a standard dose of 100 mg/day, 10% of the patients were nonresponders.</description><identifier>ISSN: 1076-0296</identifier><identifier>EISSN: 1938-2723</identifier><identifier>DOI: 10.1177/107602960100700305</identifier><identifier>PMID: 11441981</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Acids ; Aged ; Aged, 80 and over ; Arachidonic Acid - pharmacology ; Aspirin - administration & dosage ; Aspirin - therapeutic use ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Middle Aged ; Platelet Aggregation - drug effects ; Platelet Aggregation Inhibitors - administration & dosage ; Platelet Aggregation Inhibitors - therapeutic use ; Platelet Function Tests ; Thrombophilia - blood ; Thrombophilia - complications ; Thrombophilia - drug therapy</subject><ispartof>Clinical and applied thrombosis/hemostasis, 2001-07, Vol.7 (3), p.209-213</ispartof><rights>Copyright SAGE PUBLICATIONS, INC. Jul 2001</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-5448b084d5f7722b749f72f87429366d43a591038b420be9de09ad8400eae2f83</citedby><cites>FETCH-LOGICAL-c411t-5448b084d5f7722b749f72f87429366d43a591038b420be9de09ad8400eae2f83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/107602960100700305$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/107602960100700305$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,778,782,21949,27836,27907,27908,44928,45316</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/107602960100700305?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11441981$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Syrbe, Günter</creatorcontrib><creatorcontrib>Redlich, Helge</creatorcontrib><creatorcontrib>Weidlich, Bärbel</creatorcontrib><creatorcontrib>Ludwig, Jochen</creatorcontrib><creatorcontrib>Kopitzsch, Sibylle</creatorcontrib><creatorcontrib>Göckeritz, Anke</creatorcontrib><creatorcontrib>Herzog, Karin</creatorcontrib><title>Individual Dosing of ASA Prophylaxis by Controlling Platelet Aggregation</title><title>Clinical and applied thrombosis/hemostasis</title><addtitle>Clin Appl Thromb Hemost</addtitle><description>Acetylsalicylic acid is widely used in the primary and secondary prevention of cardiovascular diseases. In the current study, we used platelet aggregation ex vivo in platelet-rich plasma induced with arachidonic acid as a routine method for the determination of the individual dose of acetylsalicylic acid necessary to inhibit platelet aggregation in 108 patients with cardiovascular diseases. In 40% of all patients studied, a dose of 30 mg/day was sufficient. to block the arachidonic acid-induced platelet aggregation nearly completely. In 50% of all patients, a dose of 100 mg/day was necessary. In 10% of all patients, the dose had to be further increased to 300 mg/day or even to 500 mg/day to inhibit platelet aggregation nearly completely. These results demonstrate that platelet aggregation can be used as a simple routine laboratory method to control acetylsalicylic acid treatment in patients with cardiovascular diseases and to determine individual doses of acetylsalicylic acid for a nearly complete inhibition of platelet aggregation. With a standard dose of 100 mg/day, 10% of the patients were nonresponders.</description><subject>Acids</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Arachidonic Acid - pharmacology</subject><subject>Aspirin - administration & dosage</subject><subject>Aspirin - therapeutic use</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Platelet Aggregation - drug effects</subject><subject>Platelet Aggregation Inhibitors - administration & dosage</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Platelet Function Tests</subject><subject>Thrombophilia - blood</subject><subject>Thrombophilia - complications</subject><subject>Thrombophilia - drug therapy</subject><issn>1076-0296</issn><issn>1938-2723</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp90F1LwzAUBuAgipvTP-CFFATv6k4-2iSXZX5sMHCgXpd0TWtH1sykFffvzdhgoOBVAnnOm8OL0DWGe4w5H2PgKRCZAgbgABSSEzTEkoqYcEJPwz2AeCcG6ML7FQCWqUzP0QBjxrAUeIims7ZsvpqyVyZ6sL5p68hWUfaaRQtnNx9bo74bHxXbaGLbzlljdmJhVKeN7qKsrp2uVdfY9hKdVcp4fXU4R-j96fFtMo3nL8-zSTaPlwzjLk4YEwUIViYV54QUnMmKk0pwRiRN05JRlUgMVBSMQKFlqUGqUjAArXRwdITu9rkbZz977bt83filNka12vY-5yC5IJQFePsLrmzv2rBbHp5DOuMEB0X2aums905X-cY1a-W2OYZ813L-t-UwdHOI7ou1Lo8jh1oDGO-BV7U-_vtP5A_IvYIR</recordid><startdate>20010701</startdate><enddate>20010701</enddate><creator>Syrbe, Günter</creator><creator>Redlich, Helge</creator><creator>Weidlich, Bärbel</creator><creator>Ludwig, Jochen</creator><creator>Kopitzsch, Sibylle</creator><creator>Göckeritz, Anke</creator><creator>Herzog, Karin</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20010701</creationdate><title>Individual Dosing of ASA Prophylaxis by Controlling Platelet Aggregation</title><author>Syrbe, Günter ; Redlich, Helge ; Weidlich, Bärbel ; Ludwig, Jochen ; Kopitzsch, Sibylle ; Göckeritz, Anke ; Herzog, Karin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-5448b084d5f7722b749f72f87429366d43a591038b420be9de09ad8400eae2f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Acids</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Arachidonic Acid - pharmacology</topic><topic>Aspirin - administration & dosage</topic><topic>Aspirin - therapeutic use</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Platelet Aggregation - drug effects</topic><topic>Platelet Aggregation Inhibitors - administration & dosage</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Platelet Function Tests</topic><topic>Thrombophilia - blood</topic><topic>Thrombophilia - complications</topic><topic>Thrombophilia - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Syrbe, Günter</creatorcontrib><creatorcontrib>Redlich, Helge</creatorcontrib><creatorcontrib>Weidlich, Bärbel</creatorcontrib><creatorcontrib>Ludwig, Jochen</creatorcontrib><creatorcontrib>Kopitzsch, Sibylle</creatorcontrib><creatorcontrib>Göckeritz, Anke</creatorcontrib><creatorcontrib>Herzog, Karin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and applied thrombosis/hemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Syrbe, Günter</au><au>Redlich, Helge</au><au>Weidlich, Bärbel</au><au>Ludwig, Jochen</au><au>Kopitzsch, Sibylle</au><au>Göckeritz, Anke</au><au>Herzog, Karin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Individual Dosing of ASA Prophylaxis by Controlling Platelet Aggregation</atitle><jtitle>Clinical and applied thrombosis/hemostasis</jtitle><addtitle>Clin Appl Thromb Hemost</addtitle><date>2001-07-01</date><risdate>2001</risdate><volume>7</volume><issue>3</issue><spage>209</spage><epage>213</epage><pages>209-213</pages><issn>1076-0296</issn><eissn>1938-2723</eissn><abstract>Acetylsalicylic acid is widely used in the primary and secondary prevention of cardiovascular diseases. In the current study, we used platelet aggregation ex vivo in platelet-rich plasma induced with arachidonic acid as a routine method for the determination of the individual dose of acetylsalicylic acid necessary to inhibit platelet aggregation in 108 patients with cardiovascular diseases. In 40% of all patients studied, a dose of 30 mg/day was sufficient. to block the arachidonic acid-induced platelet aggregation nearly completely. In 50% of all patients, a dose of 100 mg/day was necessary. In 10% of all patients, the dose had to be further increased to 300 mg/day or even to 500 mg/day to inhibit platelet aggregation nearly completely. These results demonstrate that platelet aggregation can be used as a simple routine laboratory method to control acetylsalicylic acid treatment in patients with cardiovascular diseases and to determine individual doses of acetylsalicylic acid for a nearly complete inhibition of platelet aggregation. With a standard dose of 100 mg/day, 10% of the patients were nonresponders.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>11441981</pmid><doi>10.1177/107602960100700305</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1076-0296 |
| ispartof | Clinical and applied thrombosis/hemostasis, 2001-07, Vol.7 (3), p.209-213 |
| issn | 1076-0296 1938-2723 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70978234 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Acids Aged Aged, 80 and over Arachidonic Acid - pharmacology Aspirin - administration & dosage Aspirin - therapeutic use Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Dose-Response Relationship, Drug Female Humans Male Middle Aged Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - therapeutic use Platelet Function Tests Thrombophilia - blood Thrombophilia - complications Thrombophilia - drug therapy |
| title | Individual Dosing of ASA Prophylaxis by Controlling Platelet Aggregation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T00%3A14%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Individual%20Dosing%20of%20ASA%20Prophylaxis%20by%20Controlling%20Platelet%20Aggregation&rft.jtitle=Clinical%20and%20applied%20thrombosis/hemostasis&rft.au=Syrbe,%20G%C3%BCnter&rft.date=2001-07-01&rft.volume=7&rft.issue=3&rft.spage=209&rft.epage=213&rft.pages=209-213&rft.issn=1076-0296&rft.eissn=1938-2723&rft_id=info:doi/10.1177/107602960100700305&rft_dat=%3Cproquest_AFRWT%3E2344204721%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2344204721&rft_id=info:pmid/11441981&rft_sage_id=10.1177_107602960100700305&rfr_iscdi=true |